Gaucher disease is a rare metabolic condition that causes a fatty substance to build up in the organs and bones. Patients can suffer liver enlargement, anemia, and reduced platelets; they experience fatigue, bone infarctions, and permanent disability or death.
Family members who care for patients with Gaucher disease (GD) reported lower health-related quality of life (HRQOL) scores than the general population in every area of an online survey, according to a recent study conducted in China.
Investigators from Harbin Medical University in Heilongjiang, China, reported the survey results last month in Molecular Genetics and Genomic Medicine.
Forty-nine family caregivers completed the Medical Outcome Study Short Form-36 (SF-36), a questionnaire that records self-assessments in anxiety, depression, and perceived social support; along with measures of physical function and limitation, social and demographic data, and an index of each person’s perception of hope in the future. Participants were recruited through the China Gaucher disease family exchange group, a large GD platform that allows persons interested in the disease to share information.
Gaucher disease is a rare metabolic condition that causes a fatty substance called glucosylceramide to build up in the organs and bones. While rare, it is inherited and progressive, so caregivers know that when a single family member develops GD, there is a chance that others may have the condition. Patients with GD suffer severe symptoms that include liver enlargement, anemia, and reduced platelets; they experience extreme fatigue, bone infarctions and permanent disability or death.
Family caregivers, typically parents or a spouse, take on the physical and emotional demands of providing for the person with GD, almost always without compensation, at least in China. Their study sought to explore the burden of rare disease beyond the patient.
“In addition to the personal experience of suffering, rare diseases are also a family event,” the authors write. “As is the case with most chronic conditions, rare diseases have a major impact on the daily life of a patient's whole family.”
Because the SF-36 is a widely used tool, investigators could compare results from the family caregivers across 8 measure clusters, or domains. The family caregivers (FC) scored lower than the general population (GP) of China across all domains (P < .0001 for all comparisons). Results were:
The investigators found that caregiving help from others, anxiety, perceived disease severity, and medical insurance type were significant predictors of the mental health component of the summary scores.
Family caregivers outside China’s cities, who had New Rural Cooperative Medical Care insurance, had lower scores for the mental health component compared with urban workers, which the authors speculated may be related to differing reimbursement schemes for drugs for GD. In more developed areas, a different insurance system with improved reimbursement covers therapies for the condition, which reduces the economic burden on family caregivers.
“However, patients in rural areas without such coverage had huge financial burdens,” the authors wrote. “This highlighted an urgent need for reasonable and impartial medical insurance to help ease family financial burdens across regions.”
Reference
Xu J, Bao H, Qi X, et al. Family caregivers of rare disease: A survey on health-related quality of life in family caregivers for Gaucher disease patients in China. Mol Genet Genom Med. Published online August 13, 2021. doi:10.1002/mgg3.1760
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More